Clinical Trial Update: A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis [Phase 3]

View source ↗

Summary

Phase 3 trial update for subcutaneous Mircera as maintenance therapy for anemia in chronic kidney disease not on dialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• MIRCERA (METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 3 | Status: COMPLETED